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Background: The ABC phenomenon is described as a syndrome of accelerated clearance of 
polyethylene glycol (PEG)-modified liposomes from the bloodstream when repeatedly injected, 
with their increased accumulation in the liver and spleen.
Methods: To clarify this immune response phenomenon, we evaluated a novel modified 
pH-  sensitive liposome with a cleavable double smart PEG-lipid derivative (mPEG-Hz-CHEMS).
Results: The ABC phenomenon in mice was brought about by repeated injection of   conventional 
PEG-PE liposomes and was accompanied by a greatly increased uptake in the liver. However, 
a slight ABC phenomenon was brought about by repeated injection of mPEG-CHEMS liposomes 
and was accompanied by only a slightly increased uptake in the liver, and repeated injection of 
mPEG-Hz-CHEMS liposomes did not induce the ABC phenomenon and there was no increase 
in liver accumulation. This finding indicates that the cleavable mPEG-Hz-CHEMS derivative 
could lessen or eliminate the ABC phenomenon induced by repeated injection of PEGylated 
liposomes.
Conclusion: This research has shed some light on a solution to the ABC phenomenon using 
a cleavable PEG-Hz-CHEMS derivative encapsulated in nanoparticles.
Keywords: accelerated blood clearance, double smart, cleavable, mPEG-lipid derivates, 
pH-sensitive liposome
Introduction
Many liposome studies have been undertaken to develop a wide variety of amphiphilic-
associated conjugates containing a polyethylene glycol (PEG) segment as a modifier, 
such as PEG bonded to dimyristoyl phosphatidylethanolamine (DMPE-PEG)1 or to 
distearoyl phosphatidylethanolamine/methoxypolyethylene glycol (DSPE-PEG).2 
PEG enhances blood levels of the conjugate, but when the drug carrier is intended 
for intracellular penetration, PEG often prevents normal interaction of the conjugated 
drug with cells.3 According to the recent literature, PEGylated liposomes have also 
been shown to induce a significant immune response, known as the accelerated blood 
clearance (ABC) phenomenon, when repeatedly injected into the same animal. The 
ABC phenomenon is described as a syndrome of accelerated blood clearance whereby 
repeated injection of PEGylated nanoparticles can cause their rapid clearance from the 
bloodstream, with increased accumulation in the liver and spleen.4–6
The ABC phenomenon represents a barrier in research and the clinical use of 
PEGylated nanocarriers, such as liposomes, nanoparticles, microemulsions, or even 
Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
2053
ORIGINAL RESEARCH
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/IJN.S24344International Journal of Nanomedicine 2011:6
PEGylated proteins. Lu et al7 found that cationic bovine 
serum albumin-conjugated polyethyleneglycol-polylactide 
(PEG-PLA) nanoparticles could induce the ABC phenomenon 
with repeated injection of PEGylated nanoparticles. Ishihara 
et al8 also found that the ABC phenomenon could appear when 
PEG-PLA-modified nanoparticles were administered.
Many researchers have studied the ABC phenomenon, 
but there has not yet been any feasible solution to avoid or 
alleviate this problem. Judge et al9 and Semple et al10 used 
PEGylated lipids with smaller C14 lipid anchors in modi-
fied liposomes and found that the PEG dissociating from the 
particles increased and the ABC phenomenon was avoided. 
Some researchers have made efforts to alter the linkage 
between the lipids and PEG and use them in the liposome. 
Romberg et al11 have replaced PEG-modified liposomes with 
polyamino acid polyhydroxyethyl-L-asparagine (PHEA). 
PHEA liposomes have shown favorably long circulation times 
compared with PEGylated liposomes, and a second dose of 
PHEA liposomes given seven days after the first injection is 
more slowly cleared from the blood circulation than a second 
dose of PEG liposomes.
Esterase belongs to the group of plasma functionality 
enzymes that include carboxylesterase and cholinesterase.12 
Mammalian esterases distribute widely in the plasma and 
many organs and tissues. They efficiently catalyze the break-
age of ester bonds or thioester bonds to free acids from 
endogenous or exogenous materials.13,14 Xu et al15,16 synthe-
sized two PEG-lipid derivatives that linked via a single ester 
band so that PEG could be cleaved by esterase in plasma. 
The vesicles or liposomes modified by different PEG-lipid 
derivates (PEG-CHEMS or PEG-CHMC) could reduce or 
avoid occurrence of the ABC phenomenon. However, the 
capacity of PEG-CHEMS with a single ester bond is still 
not strong and requires further investigation.
In this study, we prepared modified pH-sensitive lipo-
somes with mPEG-Hz-CHEMS, a cleavable PEG-lipid 
derivative and control mPEG-CHEMS.17–19 A schematic 
diagram of the strategy is shown in Figure 1. The modified 
pH-sensitive liposomes accumulate in tumor via the enhanced 
permeability and retention effect. We linked PEG to choles-
terol by two ester bonds and one pH-sensitive hydrazone, 
with the expectation that the chemical bond would gradually 
be cleaved in serum and at lower pH conditions in vivo. The 
PEG was then detached from the surface of the liposome, 
allowing the liposome to associate with the tumor cell sur-
face, followed by cellular uptake. We assume that because 
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Figure 1 Schematic diagram of the strategy for double cleavable smart mPEG-Hz-CHEMS-modified liposomes. 
Abbreviation: mPEG-Hz-CHEMS, methoxy polyethylene glycol 2000-hydrazone-cholesteryl hemisuccinate.
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PEG dissociates from the surface of the particle, the ABC 
phenomenon is avoided. Compared with mPEG-CHEMS, 
mPEG-Hz-CHEMS could have novel dual features, both at 
a lower pH and as an esterase. In addition, cleavable mPEG-
Hz-CHEMS-modified liposomes have a long circulation time. 
Therefore, the purpose of this study was to design double 
smart mPEG-Hz-CHEMS-modified liposomes to reduce the 
likelihood of the ABC phenomenon.
Materials and methods
Soybean phosphatidylcholine (S100PC) was purchased from 
Dongshang Co Ltd (Shanghai, China). mPEG-DSPE was 
obtained from Lipoid (Ludwigshafen, Germany).   Cholesterol 
(Chol) was obtained from China Medicine Shanghai 
  Chemical Reagent Corporation (Shanghai, China). Paclitaxel 
(PTX) was supplied by Taihua Natural Plant Pharmaceuti-
cal Co Ltd (Xi’an Shaanxi, China). PEG2000-CHEMS and 
PEG2000-Hz-Chol were synthesized in our laboratory. All 
other chemicals were of analytical grade.
Animals
Five-week-old female BALB/c mice were obtained from 
Shanghai SLAC Laboratory Animal Co Ltd (Shanghai, 
China). The animals had free access to water and rat chow. 
All the animal experiments were in accordance with the 
Guide for the Care and Use of Laboratory Animals published 
by the National Institutes of Health.
Preparation of liposomes
Conventional PEG-DSPE liposomes composed of S100PC/
Chol/PEG-DSPE/PTX (90:10:3:3), mPEG-CHEMS lipo-
somes composed of S100PC/Chol/PEG-CHEMS/PTX 
(90:10:3:3), and pH-sensitive mPEG-Hz-CHEMS liposomes 
composed of S100PC/Chol/ mPEG2000-Hz-CHEMS/PTX 
(90:10:3:3) were prepared by the thin-film hydration method. 
Briefly, the hydrophobic excipients, PTX, cholesterol, and 
lipids were dissolved in chloroform and transferred into 
a suitable conical flask. The flask was evaporated under 
reduced pressure. The dry lipid formed was hydrated with 
phosphate-buffered saline (pH 7.4). The liposomal suspen-
sion was filtered through 0.2 µm polycarbonate filters and 
stored at 4°C until use.
Pharmacokinetic and tissue  
distribution study
To assess the effect of different liposomes on the pharma-
cokinetic and tissue distribution of PTX, BALB/c mice 
(18–22 g) were used in following formulations (Table 1) 
after intravenous administration via the caudal vein at the 
dose of 20 mg/kg bodyweight. The first injection used 
empty PEGylated liposomes, which were injected via the 
tail vein. Control animals received phosphate-buffered 
saline instead of the liposomes. The interval between the 
two injections was three days. For the second injection, 
liposomes were injected intravenously via the tail vein. 
Injection protocols for the liposomes are presented in 
Table 1. A-01 represents the first injection using empty 
mPEG-PE liposomes instead of phosphate-buffered saline, 
while the second injection comprised mPEG-PE lipo-
somes via the tail vein. A-02 represents the first injection 
using mPEG-PE liposomes, and the second injection also 
comprised mPEG-PE liposomes. B-01 denotes the first 
injection using empty mPEG-CHEMS liposomes instead 
of phosphate-buffered saline, while the second injection 
was of mPEG-CHEMS liposomes via the tail vein. B-02 
denotes the first injection using mPEG-PE liposomes, while 
the second injection was also of mPEG-CHEMS liposomes. 
C-01 represents the first injection using empty mPEG-Hz-
CHEMS liposomes instead of phosphate-buffered saline, 
while the second injection was of mPEG-Hz-CHEMS 
liposomes via the tail vein. C-02 denotes the first injection 
using mPEG-Hz-CHEMS liposomes, while the second 
injection also contained mPEG-PE liposomes.
At hours 0.25, 0.5, 1, 2, 4, 6, 8, and 12 following injection, 
blood samples were collected from the eyes of six mice in 
each group, after which the mice were sacrificed by cervical 
dislocation. Plasma was obtained by centrifugation at 5000 
rpm for 10 minutes. The liver and spleen were removed 
and washed twice with physiological solution (0.9% NaCl), 
weighed, and homogenized. The plasma and tissue samples 
were kept at −20°C until analysis.
Analytical procedure
A 140 µL aliquot blood sample, 10 µL of internal standard 
(Diazepam in methanol), and 290 µL of acetonitrile were 
Table 1 Injection protocols for liposomes
First injection Second injection
A-01 PBS mPEG-PE-L
A-02 mPEG-PE-L mPEG-PE-L
B-01 PBS mPEG-CHEMS-L
B-02 mPEG-CHEMS-L mPEG-CHEMS-L
C-01 PBS mPEG-Hz-CHEMS-L
C-02 mPEG-Hz-CHEMS-L mPEG-Hz-CHEMS-L
Abbreviations:  mPEG-Hz-CHEMS,  methoxy  polyethylene  glycol  2000-hydrazone-
cholesteryl hemisuccinate; mPEG-CHEMS, methoxypolyethylene glycol 2000-cholesteryl 
hemisuccinate; mPEG-PE, methoxypolyethylene glycol 2000-distearoyl phosphatidyl- 
ethanolamine; CHEMS, cholesteryl hemisuccinate; L, liposomes.
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added to a protein precipitation tube. The mixture was 
vortexed for five minutes and centrifuged at 8000 rpm for 
10 minutes. Then 20 µL of the solution were injected into 
a high-pressure liquid chromatography (HPLC) system. 
A 150 µL aliquot of homogenate from the liver and spleen, 
10 µL of internal standard (Diazepard in methanol) and 
290 µL of acetonitrile were added. The mixture was vor-
texed for five minutes and centrifuged at 15,000 rpm for 
10 minutes, and 20 µL of the supernatant was then injected 
into the HPLC system.
The concentrations of PTX in plasma and tissue samples 
were assayed by an HPLC method. The HPLC was equipped 
with a reverse-phase column (4.6 mm × 250 mm, Hanbon, 
Jiangsu, China) at 35°C and an ultraviolet spectrophotom-
eter (Agilent Technologies, Palo Alto, CA). The mobile 
phase was a mixture of methanol and water (72:28 v/v). The 
samples were delivered at a flow rate of 1.0 mL/min and 
detected at a wavelength of 227 nm.
Statistical analysis
Statistical comparisons were performed using the Student’s 
t-test for the two groups, and one-way analysis of variance 
for multiple groups. P , 0.05 was considered to be statisti-
cally significant.
Results and discussion
Effect of repeated injections on 
pharmacokinetics of PEGylated liposomes
The structure and 1H-NMR spectrum of mPEG-Hz-CHEMS 
is shown in Figure 2. The pharmacokinetics of PEG-lipid-
modified liposomes in mice were evaluated after the first and 
second injections. There was an obvious ABC phenomenon 
with the conventional mPEG-PE modified liposomes. 
The plasma PTX concentration decreased significantly 
(P , 0.05) after repeated injections of mPEG-PE liposomes 
(Figure 3A-02).
There was a sharp increase in plasma clearance rate after 
repeated injections of the mPEG-PE liposomes (Figure 3 
and Table 3). However, the cleavable PEG-lipid derivative-
modified liposomes showed different pharmacokinetics 
after the repeat injection compared with the conventional 
mPEG-PE liposomes. The plasma PTX concentration did 
not decrease significantly after repeated injections, either in 
the mPEG-CHEMS liposomes and pH-sensitive mPEG-Hz-
CHEMS liposomes (Figures 4 and 5, Table 3).
As shown in Figure 4, the plasma PTX concentration in 
the B-01 group at each time point was slightly higher than 
that in the B-02 group (mPEG-CHEMS liposomes). The dif-
ferent PEGylated liposomes have different   characteristics. 
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Figure 2 Structure and 1H-NMR spectra of mPEG-Hz-CHEMS in CDCl3. Mean particle size of different liposomes ranged in size from 100 to 200 nm with no significant 
differences. The mean zeta potential of the different liposomes were also similar. The entrapment efficiency of the different liposomes was determined to be above 90%   
(see Table 2). 
Abbreviation: mPEG-Hz-CHEMS, methoxy polyethylene glycol 2000-hydrazone-cholesteryl hemisuccinate.
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mPEG-Hz-CHEMS have double pH-sensitive hydra-
zone and esterase-sensitive ester, which could be easily 
cleavable. mPEG-CHEMS has only esterase-sensitive ester, 
while mPEG-PE is not steady under lower pH and esterase 
conditions. The main pharmacokinetic parameters of different 
liposomes also indicate this phenomenon (Table 3).
However, as shown in Figure 5 and Table 3, there 
was no significant difference between the C-01 and 
C-02 groups (mPEG-Hz-CHEMS liposomes). Blood clear-
ance curves and plasma clearance rate in the C groups 
were basically the same. That is, mPEG-CHEMS-modified 
liposomes could alleviate the ABC phenomenon, while 
  mPEG-Hz-CHEMS-modified liposomes could avoid the 
ABC phenomenon.
Effect of repeated injections on 
biodistribution of PEGylated liposomes
With regards to biodistribution of the mPEG-PE liposomes, 
there was a markedly increased uptake in the liver after the 
second dose, but no significant difference in the spleen. As 
shown in Figure 6, the accumulated amount of PTX in the 
liver increased after the second dose (P , 0.05). However, 
compared with mPEG-PE liposomes, the accumulated 
amount of PTX in the liver and spleen was not changed 
in mPEG-CHEMS liposomes and mPEG-Hz-CHEMS 
liposomes. As shown in Figure 7, mPEG-CHEMS modified 
liposomes only induced a slight ABC phenomenon which 
could alleviate the ABC phenomenon. As shown in Figure 8, 
repeated injection of mPEG-Hz-CHEMS liposomes caused 
no increase in liver and spleen accumulation. From the results 
above, mPEG-Hz-CHEMS-modified liposomes could avoid 
the ABC phenomenon.
Table 2 Physicochemical parameters of different liposomes
Liposomes Particle  
size  
(nm)
Zeta  
potential  
(mV)
Entrapment  
efficiency (%)
mPEG-PE-L 113.2 ± 8.3 −19.6 ± 4.0 92.6 ± 3.6
mPEG-CHEMS-L 125.4 ± 7.2 −24.1 ± 3.6 91.2 ± 3.4
mPEG-Hz-CHEMS-L 120.3 ± 4.6 −21.2 ± 3.4 94.4 ± 4.2
Abbreviations: mPEG-Hz-CHEMS, methoxy polyethylene glycol 2000-  hydrazone-
cholesteryl  hemisuccinate;  mPEG-CHEMS,  methoxypolyethylene  glycol  2000-
  cholesteryl  hemisuccinate;  mPEG-PE,  methoxypolyethylene  glycol  2000- 
distearoyl phosphatidylethanolamine; L, liposomes.
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Figure 3 Blood clearance of paclitaxel in mice after a first and second injection of mPEG-PE liposomes (n = 6). 
Abbreviation: mPEG-PE, methoxy polyethylene glycol 2000-distearoyl phosphatidylethanolamine.
Table 3   Main  pharmacokinetic  parameters  of  different 
liposomes
Parameters A-01 A-02 B-01 B-02 C-01 C-02
t1/2α (hours) 1.01 0.23 0.31 0.32 0.29 0.26
t1/2β (hours) 12.73 2.89 5.88 4.05 4.77 4.54
Clearance (µg/mL/hour) 0.18 0.60 0.32 0.48 0.23 0.22
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Figure 4 Blood clearance of paclitaxel in mice after a first and second injection of mPEG-CHEMS liposomes (n = 6). 
Abbreviation: mPEG-CHEMS, methoxy polyethylene glycol 2000-cholesteryl hemisuccinate.
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Figure 5 Blood clearance of paclitaxel in mice after a first and second injection of mPEG-Hz-CHEMS liposomes (n = 6). 
Abbreviation: mPEG-Hz-CHEMS, methoxy polyethylene glycol 2000-hydrazone-cholesteryl hemisuccinate.
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Discussion
The ABC phenomenon is important for the development of 
drug delivery systems, especially for nanoparticles in the case 
of repeated injection of nanomedicines. Researchers have 
used different animal models to investigate the mechanism 
of the ABC phenomenon, including rats, mice, rhesus mon-
keys, and rabbits, among others. Dams et al demonstrated 
that rhesus monkeys and rats could bring out the ABC phe-
nomenon after repeated injection of PEGylated liposomes, 
whereas mice could not.20 Ishida et al have studied the first 
liposomal characteristics that affect the ABC phenomenon 
and demonstrated that an intense accelerated clearance can 
be induced in mice.21
Although the conclusion from animal experiments might 
not be fully consistent with the clinical manifestations of 
liposomes, when there is a need for repeated injections, 
thorough study of their distribution in the body and their 
pharmacokinetics is necessary. Many researchers have sought 
a possible solution for the ABC phenomenon. Xu et al have 
investigated16 vesicles or liposomes modified by different 
PEG-lipid derivatives (PEG-CHEMS or PEG-CHMC) that 
could reduce or avoid the ABC phenomenon. In our stud-
ies, pH-sensitive liposomes modified by PEG-lipid deriva-
tives (PEG-Hz-CHEMS) showed better PEG cleavage rates 
when incubated in serum. The PEG-Hz-CHEMS was easily 
degraded at pH 5.5 (half-life 6.7 hours), while it has higher 
stability at physiological pH (half-life 40.9 hours).17
Due to the pH-sensitive hydrazone bond, the degree of 
PEG cleavage from PEG-Hz-CHEMS was higher than that 
from PEG-CHEMS, based on pH-insensitive ester bands and 
noncleavable PEG-CHOL and PEG-DSPE. This is consistent 
with the conclusion reached by Xu et al.16 When rats received 
repeated injections of PEG-CHEMS-modified liposomes, 
there were minor occurrences of the ABC   phenomenon, which 
disappeared with PEG-Hz-CHEMS. However, PEG-PE and 
PEG-CHOL-modified liposomes produced a significant ABC 
phenomenon. Our results showed that the phenomenon was 
more obvious with lower degrees of PEG cleavage (PEG-Hz-
CHEMS . PEG-CHEMS . PEG-CHOL . PEG-DSPE). 
Therefore, our hypothesis was that a first injection of cleavable 
PEG-lipid derivative-modified liposomes could reduce or 
avoid the ABC phenomenon.
When we adopted the cleavable pH-sensitive PEG-Hz-
CHEMS to modify liposomes, the ABC phenomenon was 
almost eliminated. In studies of the ABC phenomenon, the sec-
ond injected liposomes have usually been tracer-labeled with 
technetium (99 mTc-PEG)6,10 or 3H-CHE. However, because 
this method needs to be carried out by skilled   personnel and 
with strict security precautions, its   applications are limited. Xu 
et al17 used calcein, a water-soluble fluorescence probe, to mark 
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Figure 6 Biodistribution of paclitaxel in mice after a first and second injection of 
mPEG-PE liposomes (n = 6). 
Abbreviation: mPEG-PE, methoxypolyethylene glycol 2000-distearoyl phosphatid-
ylethanolamine.
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Figure 7 Biodistribution of paclitaxel in mice after a first and second injection of 
mPEG-CHEMS liposomes (n = 6). 
Abbreviation:  mPEG-CHEMS,  methoxypolyethylene  glycol  2000-cholesteryl 
hemisuccinate.
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Figure 8 Biodistribution of paclitaxel in mice after a first and second injection of 
mPEG-Hz-CHEMS liposomes (n = 6). 
Abbreviation: mPEG-Hz-CHEMS, methoxypolyethylene glycol 2000-hydrazone-
cholesteryl hemisuccinate.
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the inner water phase of liposomes and vesicles to investigate 
the ABC phenomenon. Compared with radioimmunoassay, 
fluorescence labeling has no radioactive contamination and 
is easy to perform. Moreover, the calcein marker can reflect 
overall changes in liposomes in the body, while a tracer marker 
can only express the changes in membrane components. How-
ever, the calcein marker also has some limitations, especially 
in that it does not reflect the characteristics of a poorly water 
soluble drug, as is the case with many antitumor drugs. PTX, 
the first of the microtubule-stabilizing agents, is one of the most 
successful anticancer drugs and shows potency against a broad 
spectrum of cancers, especially carcinomas of the breast, ovary 
and lung.22,23 It is currently marketed in a vehicle composed of 
Cremophor® EL (polyethoxylated castor oil) and ethanol due 
to its low aqueous solubility.24,25 Comparing 3H-CHE label-
ing and fluorescence labeling, the PTX marker could better 
reflect its real pharmacokinetic behavior in terms of the ABC 
phenomenon. In this study, we studied the effect on the ABC 
phenomenon of novel pH-sensitive liposomes with cleavable 
pH-sensitive PEG-Hz-CHEMS liposomes containing PTX.
Conclusion
We modified liposomes by mPEG-Hz-CHEMS via cleav-
able pH-responsive hydrazone and esterase-catalyzed ester 
linkages so that the PEGylated coating can be efficiently 
removed by the lower pH and esterase in the serum. This is 
the first time hydrazone and ester esterase-cleavable linkers 
have been utilized simultaneously as an effective strategy for 
PEG-lipid cleavage. The ABC phenomenon was induced by 
repeated injection of PEGylated liposomes into the rat and 
was accompanied by substantially increased uptake into the 
liver. Repeated injection of the conventional and noncleavable 
PEG-lipid derivative-modified microparticles induced the 
ABC phenomenon. We used cleavable esterase-catalyzed and 
pH-responsive double smart mPEG-Hz-CHEMS to modify 
  liposomes and showed that the ABC phenomenon became 
weaker or disappeared. Therefore, cleavable esterase-  catalyzed 
and pH-responsive double smart mPEG-Hz-CHEMS can not 
only prolong the circulation time of liposomes, but also avoid 
or weaken the ABC phenomenon. These studies have paved 
the way for a solution to the ABC phenomenon using cleav-
able PEG-lipid derivatives in nanoparticles.
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